Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2021-03, Vol.35 (3), p.929-931
Hauptverfasser:	Ikegawa, Shuntaro, Meguri, Yusuke, Mizuhara, Kentaro, Fukumi, Takuya, Kobayashi, Hiroki, Sumii, Yuichi, Kondo, Takumi, Sando, Yasuhisa, Iwamoto, Miki, Asada, Noboru, Ennishi, Daisuke, Nishimori, Hisakazu, Fujii, Keiko, Fujii, Nobuharu, Fujisawa, Yuka, Imai, Toshi, Maeda, Yoshinobu, Matsuoka, Ken-ichi
Format:	Artikel
Sprache:	eng
Schlagworte:	13/31 631/250/1854/2812 631/250/251 Cancer Research Correspondence Critical Care Medicine Cyclophosphamide Cyclophosphamide - adverse effects Gene expression Genetic aspects Graft versus host reaction Health aspects Hematology Hematopoietic Stem Cell Transplantation Immune Tolerance Immunological tolerance Intensive Internal Medicine Lymphocytes T Medicine Medicine & Public Health Monoclonal antibodies Nivolumab - adverse effects Oncology Risk factors T cells T-Lymphocytes, Regulatory Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!